Different RAI dose ranges are used in the low-risk group probably because the enrolled physicians consider RAI dose elevation on the basis of clinico-social factors beyond pre-existed guidelines. Our study may enable closer harmonization of RAI therapy practice in Asian countries.
The aim of this study was to determine the role of antithyroglobulin antibody (ATA) serum as a marker of successful I-131 ablation therapy in differentiated thyroid cancer (DTC) patients with low serum thyroglobulin (Tg). A retrospective study was conducted on 60 patients (10 males and 50 females). All patients underwent posttotal thyroidectomy and received 2.96 to 3 GBq I-131 ablation. Subjects were divided into two groups with succesful and unsuccessful I-131 ablation therapies. The data of age, gender, histopathologic type, tumor size, and metastasis were collected. Preablation serum Tg and ATA level (Tg1 and ATA1) 6–12 months after ablation (Tg2 and ATA2) were measured. The success of ablation therapy was evaluated by diagnostic whole body scan (DxWBS) 6–12 months after ablation. There were no significant differences in age, gender, type of histopathology, tumor size, and nodal metastasis between the two groups. ATA2 ≤30 kIU/L were found in 23 (62.2%) subjects with successful ablation therapy, and ATA2 >30 kIU/L in 16 (69.6%) subjects belonged to the unsuccessful group (P = 0.017). Changes between ATA1 and ATA2 levels did not differ significantly in both the groups (P = 0.062). Tg1 <10 mg/L was found in 26 (57.8%) subjects with successful therapy (P = 0.037). Multivariate analysis showed ATA2 and Tg1 as the independent factors for the success of ablation therapy (P = 0.007 and 0.015). Adjusted odds ratio of postablation ATA was 5.379 [95% confidence interval (CI) 1.590 to 18.203] and preablation Tg was 5.822 (95% CI 1.418 to 23.902). ATA levels at 6–12 months after ablation, by considering the preablation Tg levels, is a useful marker to determine successful ablation therapy in WDTC patients with low serum Tg. Changes in serum ATA levels, although not statistically significant, can provide additional information about the course of the disease.
One of the important DNA repair pathways is base excision repair (BER), which plays in the human body to maintain DNA integrity, prevent cancer and DNA damage. X-ray repair cross-complementing group 1 (XRCC1) is the most important DNA repair protein in base excision repair (BER) pathways and has been reported to have a relationship with the risk of developing various cancers. The study was purposed to assess the genetic polymorphism of XRCC1 exon 6 and 10 as a risk factor for thyroid cancer. A total of 90 participants were enrolled in this study, consisted of 30 thyroid cancer patients as a case group and 60 noncancer patients as a control group. Examination of XRCC1 genotypes was carried out by using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method and statistical analysis using a Chi-square test. In this study, we reported the frequency of XRCC1 genetic polymorphism was not significantly different between cancer patients and control groups both in exon 6 and 10, and we predict that these polymorphisms were not a risk factor for thyroid cancer (P-value>0.05). In conclusion, both mutant variants of XRCC1 exon 6 and 10 are not risk factors for thyroid cancer. In further studies, it is necessary to assess genetic polymorphisms in populations with controlled non-genetic factors, such as diet, lifestyle, and environmental factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.